Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Gains from Investment Securities (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Gains from Investment Securities data on record, last reported at $1.8 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 50.69% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $463000.0, up 207.18%, while the annual FY2025 figure was $463000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached $1.8 million in Q4 2025 per MRVI's latest filing, up from -$334000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $22.5 million in Q4 2021 and bottomed at -$32.9 million in Q4 2023.
  • Average Gains from Investment Securities over 5 years is -$2105.3, with a median of $66000.0 recorded in 2023.
  • The widest YoY moves for Gains from Investment Securities: up 5133.68% in 2022, down 8864.04% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $22.5 million in 2021, then tumbled by 187.13% to -$19.6 million in 2022, then crashed by 67.83% to -$32.9 million in 2023, then soared by 103.54% to $1.2 million in 2024, then skyrocketed by 50.69% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.8 million in Q4 2025, -$334000.0 in Q3 2025, and -$1.1 million in Q2 2025.